Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Mangoceuticals announces merger with nuclear technology company Nuclea
Mangoceuticals has entered into a definitive combination agreement with Nuclea Energy under which a newly formed subsidiary will merge with Nuclea and the result will be an indirect wholly owned subsidiary of Mangoceuticals. Nuclea is developing the lead‑cooled, graphite‑moderated micro‑modular reactor Morpheus, with a power scale of roughly 3.5 MWe to 50 MWe, and envisages applications including data centers, defense facilities and remote communities. Nuclea shareholders will receive exchangeable subsidiary shares on a one‑for‑one basis, with their rights limited prior to closing to 19.99% of Mangoceuticals’ outstanding common shares; closing is subject to shareholder approval and NASDAQ/SEC approvals. » Más en de.investing.com
Mangoceuticals sues Clarity Ventures in Texas for over $73 million
Mangoceuticals has filed a lawsuit against Clarity Ventures in a Texas court seeking more than $73 million plus interest, costs and attorneys’ fees. The company alleges Clarity failed to deliver a fully functional, HIPAA-compliant ERP and e-commerce platform; Clarity denies the claims and has filed a counterclaim over allegedly unpaid invoices. Mangoceuticals says it made all payments and has since developed its own in‑house telemedicine and e-commerce platform; the stock recently suffered a sharp decline and the company reported falling revenues (down 38% to $0.47 million) with a gross margin of 60.61%. » Más en de.investing.com
Mangoceuticals plans up to $100 million Solana treasury via subsidiary Mango DAT
Mangoceuticals announced a treasury strategy to invest up to $100 million into the Solana blockchain through its newly formed subsidiary Mango DAT. The Cube Group has been appointed as asset manager; the target is staking yields of 7–8% annually with active management potential of 8–20%. To finance the plan the company intends to use its shelf registration; a successful sale of the securities is not guaranteed. Additionally, Mangoceuticals recently raised $2.5 million through a registered direct placement and is continuing to expand its telemedicine offerings after denying partnership claims with Novo Nordisk and Eli Lilly. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | jun 2026 | |
|---|---|---|
| Ingresos | 60,25 mil | 57,76 % |
| Beneficio bruto | 38,74 mil | 49,23 % |
| Beneficio neto | -1,15 M | 74,97 % |
| EBITDA | -672,42 mil | 82,61 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 6 M € |
Número de acciones | 16,97 M |
Máximo/mínimo de 52 semanas | 2,37 € - 0,14 € |
| Dividendos | No |
Beta | 2,10 |
Ratio P/E | -0,35 |
Ratio PEG | 0,00 |
Ratio P/B | 0,56 |
Ratio P/S | 22,05 |
Perfil de la empresa
| Nombre | MANGOCEUTICALS INC.NEW Aktie |
| CEO | Jacob D. Cohen |
| Empleados | 3 |
Descubrir activos
Los accionistas de MANGOCEUTICALS INC.NEW Aktie también invierten en los siguientes activos





